PER
PERCHERON THERAPEUTICS LIMITED
$0.0050
▲ +12.50%
Market cap
$8M
Turnover
$10,254
Last price
$0.0050
Day change
+12.50%
Announcements
9
Range, past year
Open 0.009 · Low 0.002 · Now 0.005 · High 0.013
Open PER in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
PER momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
28/100
Wyckoff phase
Downtrend15d
Trend stage
Neutral
1 Day
+25.0%
1 Week
+25.0%
1 Month
+0.0%
1 Year
-50.0%
RSI
55
Avg daily range
12.9%
PERCHERON THERAPEUTICS LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Downtrend, where it has been for 15 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- RSI in healthy zone (55)
Points to watch
- 60d drawdown -50.0%
- High volatility (ATR 12.9%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsPER announcements
Recent price-sensitive releases.
- 2026-09-01 Percheron raises $2.3m to fully fund clinical trial in AML Placement | Issued Capital - Other | Notice of Meeting - Other | Trading Halt Lifted
- 2026-08-28 Trading Halt Trading Halt
- 2026-08-28 Vanderbilt Health to conduct clinical trial of HMBD-002 Progress Report
- 2026-08-19 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-10 Percheron Therapeutics Announces CEO Succession CEO/Managing Director - Appointment Resignation
- 2026-07-31 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-04-30 Quarterly Activities Report and Appendix 4C
More Health Care stocks
Most traded in the same sector.